GlaxoSmithKline PLC (GSK)

GSK (NYSE:Drugs)
neg -0.10
Today's Range: 48.35 - 48.88 | GSK Avg Daily Volume: 2,869,200
Last Update: 07/31/14 - 4:07 PM EDT
Volume: 5,544,038
YTD Performance: -9.22%
Open: $48.88
Previous Close: $48.47
52 Week Range: $48.01 - $56.73
Oustanding Shares: 2,402,000,000
Market Cap: 115,368,060,000
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 2 2 2
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 1 0 0 0
Mean Rec. 3.00 2.50 2.50 2.50
Latest Dividend: 0.65
Latest Dividend Yield: 5.53%
Dividend Ex-Date: 08/06/14
Price Earnings Ratio: 16.51
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
16.51 14.80 28.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-12.46% -4.61% 9.12%
Revenue 2.30 0.00 0.00
Net Income 21.10 2.25 0.47
EPS 23.20 2.75 0.55
Earnings for GSK:
Revenue 43.71B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.79 $0.90 $3.15 $3.48
Number of Analysts 1 1 5 7
High Estimate $0.79 $0.90 $3.22 $4.10
Low Estimate $0.79 $0.90 $3.06 $3.05
Prior Year $0.92 $0.95 $3.46 $3.15
Growth Rate (Year over Year) -14.13% -5.26% -8.96% 10.39%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
McDonald's and GlaxoSmithKline are fighting against major turns of the tide.
Your portfolio could use an English touch.
Apr 23, 2014 | 8:24 AM EDT
GSK was upgraded from Hold to Buy, Argus said. Asset swap with Novartis is attractive. 
Futures point higher; blockbuster drug deal boosts European markets.

The Cloud Is the Prescription Real Money Pro($)

Medidata Solutions is focusing its cloud-computing offerings on the pharmaceutical industry.
The untold story about these stocks is how they have held up.
Aug 14, 2013 | 8:00 AM EDT
GSK was upgraded to Neutral, JP Morgan said. Upcoming catalysts balance out earnings risk. 
The UK is the next geographic hotspot. Play it with this ETF.
Jun 17, 2013 | 8:06 AM EDT
GSK earnings estimates were increased to reflect the multi-blockbuster potential of MAGE A3, said UBS. Price target goes to $54.81.

Columnist Conversations

Volume in the SPY today was nearly double its 50 day average of volume. (The graph at the bottom of the chart ...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market got beat like a rented mule today as equities posted their second worst day of the year. Geopolitical ...
down 302 now, at 16577 the dow 30 is unchanged for 2014. roll the media hype!


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.